Key result
Single-dose rFAdV-4-fiber/8b+11 vaccine provides robust multi-serotype protection against FAdV-4, FAdV-8b, and FAdV-11.
Why the study?
Concurrent infections of FAdV-4, FAdV-8b, and FAdV-11 are common in chickens, but no commercially available trivalent vaccines exist against these serotypes.
A novel recombinant trivalent vaccine provides robust immune responses and clinical protection against FAdV-4, FAdV-8b, and FAdV-11 in chickens.
Hypothesis-generating for trivalent FAdV vaccines in poultry; field trials needed before commercial adoption.
Outbreaks of hepatitis-hydropericardium syndrome (HHS) caused by fowl adenovirus serotype 4 (FAdV-4) and inclusion body hepatitis (IBH) related to FAdV-8b and FAdV-11 have been increased in chickens in China since 2015. Clinical concurrent infections of FAdV-4, FAdV-8b, and FAdV-11 are quite common, yet there are no commercially available trivalent vaccines against infection by these three serotypes. In our previous study, a bivalent vaccine based on a recombinant FAdV-4, of which fiber-1 was replaced with the fiber of FAdV-8b, has been developed. In this study, a novel recombinant rFAdV-4-fiber/8b + 11 was constructed by inserting FAdV-11 fiber gene into the 1966-bp deletion region of rFAdV-4-fiber/8b genome. The in vitro replication ability of the rFAdV-4-fiber/8b + 11 was similar to the parental FAdV-4. One dose immunization with the inactivated rFAdV-4-fiber/8b + 11 vaccine generated robust immune responses against FAdV-4, FAdV-8b, and FAdV-11, and provided efficient clinical protection against FAdV-4, FAdV-8b, and FAdV-11 challenge. This study provides a novel strategy for developing potential trivalent vaccines for the prevention and control of HHS and IBH.
No takes yet. Share an insight, caveat, or question.
Song et al. (2023) studied Hepatitis-hydropericardium syndrome (HHS) and inclusion body hepatitis (IBH) in chickens. Inactivated recombinant rFAdV-4-fiber/8b + 11 vaccine was evaluated on Immune responses and clinical protection against FAdV-4, FAdV-8b, and FAdV-11 challenge. One dose immunization with the inactivated rFAdV-4-fiber/8b + 11 vaccine generated robust immune responses and provided efficient clinical protection against FAdV-4, FAdV-8b, and FAdV-11 challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: